NapaJen Pharma Closes $12.4 Million Series C Financing
TOKYO and BURLINGAME Calif., Jan. 9, 2019 /Kyodo JBN- AsiaNet/ -- NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, has announced the closing of a $12.4 million Series C financing deal. Th...
Read more https://view-release/?pr-id=76992